

AMENDMENT

In the Claims:

The following listing reflects amendments to the claims and replaces all prior versions and listings of claims in this application.

1-4. (Cancelled)

5. (Currently amended) A carrier protein that comprises a P23TT, P32TT, P21TT, PFT3, P30TT, P2TT, HBVnc, influenza haemagglutinin (HA), HbsAg and influenza matrix (MT) CD4+ T cell epitope epitopes.

6. (Currently amended) A The carrier protein according to claim 5, that further comprises a ~~P23TT, P32TT, P21TT, PFT3, P30TT, P2TT, HBVnc, HA, HbsAg, MT and an~~ hsp70 CD4+ T cell epitope.

7-12. (Cancelled)

13. (Currently amended) A The carrier protein according to claim 37, wherein the polysaccharide is from ~~any one of the following organisms:~~ *S. pneumoniae*, *N. meningitidis*, *S. aureus*, *Klebsiella*, or *S. typhimurium*.

14. (Currently amended) A The carrier protein according to claim 37, wherein the polysaccharide is conjugated to the carrier protein by a covalent linkage.

15. (Currently amended) A The carrier protein according to claim 37, wherein the polysaccharide is conjugated to the carrier protein by reductive amination.

16. (Currently amended) A The carrier protein according to claim 37, wherein between two and ten carrier protein molecules are present for each polysaccharide molecule.

17-32. (Cancelled)

33. (Previously presented) The carrier protein according to claim 5, wherein the CD4+ T cell epitopes are human CD4+ T cell epitopes.

34. (Previously presented) The carrier protein according to claim 6, wherein the CD4+ T cell epitopes are human CD4+ T cell epitopes.

35. (Currently amended) The carrier protein according to claim 5, wherein the carrier protein is in an oligomeric form.

36. (Currently amended) The carrier protein according to claim 6, wherein the carrier protein is in an oligomeric form.

37. (Previously presented) The carrier protein according to claim 5, conjugated to a polysaccharide.

38. (Previously presented) The carrier protein according to claim 6, conjugated to a polysaccharide.

39. (Previously presented) The carrier protein according to claim 37, wherein the polysaccharide is an *Haemophilus influenzae* type B polysaccharide.

40. (Previously presented) The carrier protein according to claim 38, wherein the polysaccharide is an *Haemophilus influenzae* type B polysaccharide.

41. (Previously presented) A vaccine comprising the carrier protein according to claim 5.

42. (Previously presented) A vaccine comprising the carrier protein according to claim 6.

43. (Previously presented) A vaccine comprising the carrier protein according to claim 39.

44. (Previously presented) A vaccine comprising the carrier protein according to claim 40.